Wall Street analyst estimates for Imunon, Inc. (IMNN): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Imunon, Inc. is a clinical-stage biotechnology company dedicated to the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. The company's pipeline features GEN-1, a DNA-based immunotherapy specifically designed for the localized treatment of ovarian cancer, and ThermoDox, a proprietary heat-activated liposomal formulation of doxorubicin, currently in development for various cancer indications.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-12 | $-0.61 | ||
| 2026-08-11 | $-0.54 | $-0.87 | +37.8% |
| 2026-05-12 | $-0.84 | $-1.22 | +30.9% |
| 2026-03-31 | $-1.29 | $-1.43 | +9.8% |
| 2025-11-13 | $-1.16 | $-1.20 | +3.2% |
| 2025-08-05 | $-1.87 | $-3.09 | +39.5% |
| 2025-05-12 | $-3.65 | $-4.56 | +20.0% |
| 2025-02-27 | $-3.26 | $-4.69 | +30.5% |
Valuation Ratios
| Price / Book | 1.77 |
| EV / EBITDA | -0.54 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $500000 | $500000 | $500000 | $500000 | $500000 | $500000 | $500000 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | $500000 | $500000 | $500000 | $500000 | $500000 | $500000 | $500000 | 0 | 0 | 0 |
| Research & Development | $14.6M | $13.1M | $11.9M | $13.1M | $11.3M | $10.6M | $11.7M | $11.3M | $11.6M | $7.8M |
| Selling, General & Admin | $6.5M | $5.9M | $9.7M | $8.0M | $7.6M | $10.9M | $13.7M | $9.7M | $7.5M | $6.9M |
| Operating Expenses | $21.1M | $19.0M | $21.6M | $21.1M | $19.0M | $21.5M | $25.4M | $21.0M | $19.1M | $14.7M |
| Operating Income | -$20.6M | -$18.5M | -$21.1M | -$20.6M | -$18.5M | -$21.0M | -$24.9M | -$21.0M | -$19.1M | -$14.7M |
| EBITDA | -$20.3M | -$19.8M | -$21.2M | -$16.6M | -$21.3M | -$20.9M | -$31.7M | -$19.9M | -$17.9M | -$13.8M |
| Interest Expense | $722993 | $91756 | $712025 | $1.4M | $1.3M | $569881 | $5.0M | $197080 | 0 | 0 |
| Pre-tax Income | -$22.1M | -$20.4M | -$22.3M | -$18.7M | -$23.3M | -$22.2M | -$37.5M | -$20.8M | -$18.6M | -$14.5M |
| Income Tax | 0 | 0 | -$10.4M | -$1.8M | -$1.8M | -$1.4M | -$1.6M | -$1.3M | 0 | 0 |
| Net Income | -$22.1M | -$20.4M | -$11.9M | -$16.9M | -$21.5M | -$20.8M | -$35.9M | -$19.5M | -$18.6M | -$14.5M |
| EPS | $-2328.26 | $-532.22 | $-132.23 | $-151.01 | $-131.51 | $-748.77 | $-65.55 | $-28.14 | $-21.10 | $-6.83 |
| EPS (Diluted) | $-2328.26 | $-532.22 | $-132.23 | $-151.01 | $-131.51 | $-748.77 | $-65.55 | $-28.14 | $-21.10 | $-6.83 |
| Shares Outstanding (Diluted) | $9476 | $38983 | $89868 | $111590 | $163357 | $27737 | $547627 | $693474 | $882292 | $2.1M |
Price
| Price | $1.41 |
| Market Cap | $6M |
| Exchange | NASDAQ |
| Country | US |
Related companies: AEON · BOLT · CING · CLRB · COCP · DWTX · EVGN
Explore sector: Healthcare · Biotechnology
More sections of IMNN: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks